Daily Pill Gives Pancreatic Cancer Patients Double Life

Sun Sep 06 2026 18:14:40 GMT+0000 (Coordinated Universal Time)

FDA approves a new drug that doubles survival for pancreatic cancer, hitting a dead‑ly disease with a breakthrough daily pill.

The FDA has approved Daraxonrasib (Rasonque), a daily pill that almost doubles survival time for pancreatic cancer patients. In a trial with 500 people, those on the drug lived an average 13.2 months versus 6.6 months on standard chemotherapy. The drug targets the mutated KRAS gene common in 90% of pancreatic tumours, giving a new hope in a cancer with the highest mortality rate. Side effects were common but appeared in fewer patients than conventional chemo, and even a former senator shared his tumor shrinkage after participating in the trial. This approval marks the first major progress in treating one of the world’s deadliest cancers.

FDA Green‑Lights New Pancreatic Cancer Drug

The U.S. Food and Drug Administration has approved Daraxonrasib – sold as Rasonque – a daily pill that nearly doubles survival time for pancreatic cancer patients in clinical trials.

In a late‑stage study of 500 participants, those who took the pill lived an average of 13.2 months, compared with 6.6 months for patients on conventional chemotherapy.

The drug works by blocking the KRAS gene, mutated in more than 90 percent of pancreatic tumours and responsible for rapid cancer growth. It marks a huge step forward for a disease that has the highest cancer‑death rate and is often found too late.

Around 44 percent of patients on Daraxonrasib experienced severe side effects, lower than the 57.5 percent seen with chemo. Common issues include rash, diarrhea, nausea, fatigue and vomiting.

The FDA fast‑tracked the approval, citing “unprecedented results in an area of high unmet need.” It carried a “Breakthrough Therapy” designation this year, enabling quicker review.

Even U.S. Senator Ben Sasse, diagnosed with Stage 4 pancreatic cancer, is now in a trial for the drug and reports that his tumours have shrunk. This real‑world success story highlights the potential of the new medicine.

With roughly 67,000 new cases each year in the United States, a drug that can nearly double survival offers a promising new ray of hope for patients and families facing this devastating diagnosis.